EpitalonLongevity
Telomerase peptide studied for sleep and aging.
- Status
- Research / not approved
- Developer
- Vladimir Khavinson, St. Petersburg Institute of Bioregulation and Gerontology
- Receptors / target
- Synthetic tetrapeptide (Ala-Glu-Asp-Gly); claimed telomerase/hTERT induction and pineal/epigenetic effects, but the mechanism is unclear and not well established
- FDA-approved?
- NO
- Prescription available?
- NO
- Studied for
- aging / gerontologytelomerase & telomere researchcircadian / pineal regulationantioxidant effects
Overview
Epitalon (also Epithalon, Epithalamin) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, said to represent the active core of epithalamin, a bovine pineal-gland extract. It is marketed in research circles as an "anti-aging" / telomerase-activating peptide, but it has not been evaluated or approved by the FDA and is sold strictly as a research chemical. Critically, almost the entire foundational evidence base traces to a single research group and is old, small and largely un-replicated.
Mechanism
The headline claim is that Epitalon induces telomerase (hTERT) activity and elongates telomeres, with secondary claims of pineal/neuroendocrine and epigenetic effects. The original telomerase findings come from Khavinson-group human cell-culture experiments, and a 2025 independent in-vitro study did report dose-dependent telomere lengthening in human cell lines (via telomerase or the ALT pathway). However, a 2025 review states the mechanism "remains unclear." These effects are seen in cell culture and are not established as operative — or beneficial — in living humans.
Clinical evidence
Human evidence is minimal and weak. The widely cited elderly-cohort "mortality reduction" study tested epithalamin (the pineal extract), not synthetic Epitalon, was conducted by the originating Russian group, and reports no randomization, blinding or control detail in its abstract. A 2025 review found only two small human trials of Epitalon itself, with no replication. No modern, large, independent, placebo-controlled trial supports telomere-lengthening or lifespan extension in humans; anti-aging claims should be treated as unproven.
Safety profile
Human safety for Epitalon is essentially unstudied by modern standards: there are no published controlled safety, pharmacokinetic or long-term toxicology trials, and human half-life is not validly characterized. A specific theoretical concern is that any telomerase- or ALT-activating effect could favor survival of abnormal or cancerous cells — the 2025 cell-line study itself showed telomere elongation in breast-cancer cells — so the long-term oncologic risk is unknown and non-trivial. Research use only; no therapeutic, anti-aging or dosing claims are warranted.
- Cycles (claimed)
Khavinson-group protocols use short courses (e.g., 10–20 days, repeated), but the anti-aging/telomerase claims rest on small, largely un-replicated studies — no validated human time-course.
- Reality
There is no controlled human evidence of an effect; any longevity timeline is unproven.
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Injection-site reactions
- Generally minimal reported effects in limited studies
- Very sparse human safety data
If severe or unexpected symptoms occur, contact a qualified medical professional. PEPTIDES·INDEX does not provide medical advice.
- Human contraindication data are absent — there are no published controlled safety trials.
- Theoretical caution regarding malignancy: a telomerase/ALT-activating peptide could in principle support survival of abnormal or cancerous cells; avoid with any history of cancer.
- Avoid in pregnancy and breastfeeding — no reproductive or developmental safety data.
- No documented human drug interactionsInteraction profile uncharacterized in humans (research use only)
Compare
- vs Pinealon
The closest sibling in the Khavinson ultrashort-peptide family, with the same preclinical/single-group evidence limits; Pinealon is framed around neuroprotection where Epitalon is framed around telomerase/aging.
FAQ
Does Epitalon lengthen telomeres or extend lifespan in humans?
Unproven. The telomerase findings come from Khavinson-group cell-culture work (a 2025 independent in-vitro study did report telomere lengthening), but no modern, large, independent, placebo-controlled human trial supports telomere lengthening or lifespan extension. The famous mortality study tested epithalamin, a pineal extract, not synthetic Epitalon.
Is Epitalon FDA-approved?
No. It has not been evaluated or approved by the FDA and is sold strictly as a research chemical. Almost the entire foundational evidence base traces to one research group and is old, small and largely un-replicated.
Are there safety concerns with Epitalon?
Human safety is essentially unstudied, and there is a specific theoretical concern: any telomerase- or ALT-activating effect could favor survival of abnormal or cancerous cells. The 2025 cell-line study itself showed telomere elongation in breast-cancer cells, so long-term oncologic risk is unknown and non-trivial.
What is the difference between Epitalon and epithalamin?
Epithalamin is a natural peptide extract of the bovine pineal gland; Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide said to represent its active core. This distinction matters because the most-cited human 'mortality reduction' study used epithalamin, the extract — not synthetic Epitalon — so it cannot be cited as proof that Epitalon extends life.
How is Epitalon related to Pinealon?
Both are Khavinson-group ultrashort peptide bioregulators with the same evidence limits — preclinical, single-group and largely un-replicated. Epitalon is framed around telomerase and aging, while Pinealon (a Glu-Asp-Arg tripeptide) is framed around neuroprotection. The two are sometimes discussed or used together, but neither has controlled human trials.
Is Epitalon banned in sport?
Epitalon is not specifically named on the WADA Prohibited List, but absence is not clearance. Novel peptides can be captured by WADA catch-all provisions for non-approved substances, and an unregulated research chemical of unverified identity and purity carries inherent contamination risk for tested athletes.
Similar compounds
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.